Use the pattern recognition workspace to apply Upside Gap Two Crows recognition and other studies to Spero Therapeutics. The focus on pattern recognition signals tied to momentum and continuation helps organize trend, volatility, and risk context for Spero Therapeutics.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Upside Gap Two Crows pattern suggests that Spero Therapeutics investor sentiment is turning from bullish to bearish.
Spero Therapeutics Technical Analysis Modules
Most technical analysis of Spero Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Spero from various momentum indicators to cycle indicators. When you analyze Spero charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts. Spero Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. As a micro-cap equity, Spero Therapeutics is reviewed for growth durability, margin stability, and risk discipline. Current metrics include P/E of 81.2, P/B of 5.21, profit margin of -108.11%. Spero Therapeutics has a market cap of 138.03 M, P/E of 81.2, ROE of -95.3%.
Methodology
Unless otherwise specified, financial data for Spero Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Spero (USA Stocks:SPRO) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Spero Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Spero Therapeutics is covered by 1 analyst. Representative analyst firms may include Evercore ISI, Morgan Stanley, BMO Capital Markets, Oppenheimer & Co., Guggenheim Securities, among others. Updates may occur throughout the day.
Tracking Spero Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
Reviewing Spero Therapeutics commonly begins with financial statements and performance trends. Financial ratios provide context for profitability, efficiency, and growth trends. Selected reports below provide context for Spero Stock:
Spero Therapeutics has a market cap of 138.03 M, operating margin of -134.68%, ROE of -95.3%. See World Market Map for portfolio-level analysis. This suggests a position in Spero Therapeutics within the allocation view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Our How to Buy Spero Stock guide explains the steps to invest in Spero Therapeutics stock.Analysis related to Spero Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Quarterly Earnings Growth
0.753
Earnings Share
-0.79
Revenue Per Share
0.73
Quarterly Revenue Growth
-0.60
Return On Assets
-0.30
Understanding Spero Therapeutics includes distinguishing between market value and book value, where book value reflects Spero accounting equity. Spero Therapeutics' market capitalization is 138.03 M. With a P/B ratio of 5.21, the market values Spero Therapeutics well above its book equity. Enterprise value stands at 92.77 M. Intrinsic value is an estimate of underlying worth, separate from trading price and book value. The valuation process compares these measures for perspective.
The concept of value for Spero Therapeutics differs from its quoted price, since each reflects a different lens. For Spero Therapeutics, key inputs include a P/E ratio of 81.2, a P/B ratio of 5.21, a profit margin of -108.11%, and ROE of -95.3%. Trading price represents the transaction level agreed by market participants.
Gabriel Shpitalnik ยท Member of Macroaxis Editorial Board